The Spanish Association of Lung Cancer Patients (AEACaP) and Lung Cancer Europe (LuCE) will be hosting the webinar “ROS-1 Lung Cancer Patients” on Friday, March 26th, 2021 at 18.00 Central European Time (10 am Pacific Time). The event will provide information about the ROS1 biomarker and treatment in lung cancer, as well as research and … Continue reading AEACaP and Lung Cancer Europe (LuCE) host “ROS-1 Lung Cancer Patients” webinar on 26-Mar-2021
Today The ROS1ders published a white paper titled, “Sustaining and Accelerating Research for ROS1 Cancer.” The document summarizes key themes and subsequent discussions from two ROS1ders Research Roundtable virtual meetings, which brought together members of The ROS1ders with leading ROS1 clinicians and researchers. The report also offers a “Call to Action” to help move ROS1 … Continue reading The ROS1ders publishes report to move ROS1+ cancer research forward
For the first time, Australian ROS1+ lung cancer patients may have affordable access to Entrectnib. Currently, ROS1 patients cannot get access to Entrectnib outside of a clinical trial. We need the help of ROS1ders to make it happen. From 1 February 2020, Australian who have ROS1+ lung cancer may be able to purchase the medication … Continue reading Calling all ROS1ders! Please help Australians access Entrectinib
Lung Cancer Canada (LCC) is seeking ROS1 positive non-small cell lung cancer (NSCLC) patients and caregivers who have past or present treatment experience with ENTRECTINIB to share their experiences. This information will be used to provide patient/caregiver input that will help in determining accessibility of this drug for lung cancer patients in Canada. LCC and … Continue reading ROS1DERS: You can help Canadian ROS1+ NSCLC patients gain access to entrectinib!
Welcome to the Winter 2020 issue of ROS1derings, the newsletter of The ROS1ders! This issue contains info about on our patient-driven research, a fundraising update, a summary of current targeted therapies for ROS1+ cancers, and tips on parenting after a ROS1+ cancer diagnosis. Thanks to editors Joyce Hoelting and Jeff Wynne, and contributors Lisa Goldman, … Continue reading ROS1derings Winter 2020 (The ROS1ders newsletter)
Dear Turning Point Therapeutics, Thank you so much for inviting me to speak to your employees about my personal ROS1 lung cancer story and the work of The ROS1ders. I truly appreciate your willingness to consider a patient perspective on ways to improve awareness of and access to biomarker testing and clinical trials for cancer patients. … Continue reading Thanks to ROS1ders’ Partner Turning Point Therapeutics